U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H67N13O10
Molecular Weight 926.0749
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRV-120027

SMILES

[H][C@](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC)C(C)C)([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N[C@H](C)C(O)=O

InChI

InChIKey=XIEWFECSPPTVQN-KMIMAYJXSA-N
InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1

HIDE SMILES / InChI
TRV-120027 is a novel β-arrestin biased ligand of the angiotensin II type 1 receptor; it antagonizes canonical G-protein-mediated coupling while, in contrast to classical angiotensin II type 1 receptor antagonists, it engages β-arrestin-mediated signaling. Consequently, TRV-120027 inhibits angiotensin II-mediated vasoconstriction while, via β-arrestin coupling, it increases cardiomyocyte contractility. In preclinical studies, TRV-120027 not only produced vasodilation by antagonizing the AT1R-Gαq pathway but also enhanced cardiac performance by activating AT1R-β-arrestin signaling. Because of this unique pharmacological profile, TRV-120027 is now being evaluated in a phase II clinical trial as a novel therapeutic for acute heart failure (AHF).

Approval Year

PubMed

PubMed

TitleDatePubMed
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
2012 Sep 1

Sample Use Guides

Acute heart failure: 1, 5, or 25 mg/h of TRV-120027. Treatment was by IV infusion for 48-96 h.
Route of Administration: Intravenous
Name Type Language
D-ALANINE, N-METHYLGLYCYL-L-ARGINYL-L-VALYL-L-TYROSYL-L-ISOLEUCYL-L-HISTIDYL-L-PROLYL-
Preferred Name English
TRV-120027
Common Name English
TRV027
Code English
TRV120027
Common Name English
TRV 027
Code English
SAR-VAL-TYR-ILE-HIS-PRO-D-ALA-OH
Common Name English
TRV 027 [WHO-DD]
Common Name English
TRV-027
Code English
Code System Code Type Description
DRUG BANK
DB12199
Created by admin on Mon Mar 31 21:01:47 GMT 2025 , Edited by admin on Mon Mar 31 21:01:47 GMT 2025
PRIMARY
CAS
1234510-46-3
Created by admin on Mon Mar 31 21:01:47 GMT 2025 , Edited by admin on Mon Mar 31 21:01:47 GMT 2025
PRIMARY
SMS_ID
300000022012
Created by admin on Mon Mar 31 21:01:47 GMT 2025 , Edited by admin on Mon Mar 31 21:01:47 GMT 2025
PRIMARY
FDA UNII
J1J4P3PQZD
Created by admin on Mon Mar 31 21:01:47 GMT 2025 , Edited by admin on Mon Mar 31 21:01:47 GMT 2025
PRIMARY
PUBCHEM
3082475
Created by admin on Mon Mar 31 21:01:47 GMT 2025 , Edited by admin on Mon Mar 31 21:01:47 GMT 2025
PRIMARY